AMMONIUM PHOSPHATE, MONOBASIC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	H2O4P.H4N
Molecular Weight	115.0257
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of AMMONIUM PHOSPHATE, MONOBASIC

Structure Search

SMILES

[NH4+].OP(O)([O-])=O

InChI

InChIKey=LFVGISIMTYGQHF-UHFFFAOYSA-N

InChI=1S/H3N.H3O4P/c;1-5(2,3)4/h1H3;(H3,1,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21250045https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/18582scs031_procalAmine_lbl.pdf | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99

Phosphoric acid, also known as orthophosphoric acid, is used in dentistry and orthodontics to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed. In addition, this acid is a part of product ProcalAmine, which is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition. In combination with dextrose (glucose) and levulose (fructose), phosphoric acid relieves nausea due to upset stomach from intestinal flu, stomach flu, and food or drink indiscretions. In addition, homeopathic product, Brain power contains also phosphoric acid and this product is used to temporarily relieve symptoms of general physical weakness and listlessness, including: fatigue; sore muscles & joints; dry skin; absence of sexual desire; occasional sleeplessness.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Lose body protein 27 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/18582scs031_procalAmine_lbl.pdf	Palliative	Approved 8429	PROCALAMINE Approved Use ProcalAmine is indicated for peripheral administration in adults to preserve body protein and improve nitrogen balance in well-nourished, mildly catabolic patients who require short-term parenteral nutrition. Launch Date 1982
Nausea 63 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8dc39e1-e03e-4db8-a76d-dba72aad9a49	Palliative	Not Provided 504	Unknown Approved Use Unknown
Fatigue 46 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99	Palliative	Not Provided 504	Unknown Approved Use Unknown
Occasional sleeplessness 37 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99	Palliative	Not Provided 504	Unknown Approved Use Unknown
Sore muscles & joints 27 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58f0330d-0c16-4505-913d-26cccf42ae99	Palliative	Not Provided 504	Unknown Approved Use Unknown
Hypophosphatemia 30 Sources: http://www.iasj.net/iasj?func=fulltext&aId=44752	Diagnostic	Natural Metabolite	Unknown Approved Use Unknown
Hyperphosphatemia 30 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21250045	Diagnostic	Natural Metabolite	Unknown Approved Use Unknown
Hypophosphatemia 30 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3d066575-f361-4fcc-b1f3-3ae2be447719&type=display	Primary	Approved 8429	SODIUM PHOSPHATES INJECTION Approved Use Sodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.

PubMed

Title	Date	PubMed
Diurnal variation in the levels of glucose and related substances in healthy and diabetic subjects during starvation.	1967 Feb	5336272
Determination of inorganic phosphate in serum and saliva using a synthetic receptor.	2003 Jun 12	12790520
Amperometric biosensor for determining human salivary phosphate.	2005 Aug 15	15993373
Phosphorus amendment reduces hepatic and renal oxidative stress in mallards ingesting lead-contaminated sediments.	2006 Jun	16840252

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Name

Type

Language

AMMONIUM PHOSPHATE, MONOBASIC

Common Name

English

MONOAMMONIUM PHOSPHATE

Systematic Name

English

AMMONIUM DIHYDROGEN TETRAOXOPHOSPHATE

Common Name

English

MONOBASIC AMMONIUM PHOSPHATE

Common Name

English

PRIMARY AMMONIUM PHOSPHATE

Common Name

English

INS-342(I)

Common Name

English

AMMONIUM PHOSPHATE, MONOBASIC [MI]

Common Name

English

PHOSPHORIC ACID, MONOAMMONIUM SALT

Common Name

English

PHOSPHORIC ACID, AMMONIUM SALT (1:1)

Common Name

English

AMMONIUM DIHYDROGEN PHOSPHATE

Systematic Name

English

ACID AMMONIUM PHOSPHATE

Common Name

English

AMMONIUM DIHYDROGEN ORTHOPHOSPHATE

Systematic Name

English

NSC-57633

Code

English

MONOAMMONIUM MONOPHOSPHATE

Systematic Name

English

AMMONIUM DIHYDROGENORTHOPHOSPHATE

Systematic Name

English

E-342(I)

Common Name

English

AMMONIUM PHOSPHATE,MONOBASIC [VANDF]

Common Name

English

MONOAMMONIUM PHOSPHATE [HSDB]

Common Name

English

INS NO.342(I)

Common Name

English

AMMONIUM PHOSPHATE, MONOBASIC [FCC]

Common Name

English

Classification Tree Code System Code

JECFA EVALUATION

INS-342(I)